on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech: Unaudited results for the first nine months of 2024
Sartorius Stedim Biotech reported sales of €2,029 million for the first nine months of 2024, marking an organic decline of 3% at constant exchange rates. Recurring EBITDA amounted to €565 million with a margin of 27.8%, while net income was €129 million. The company benefited from a significant increase in orders for consumables, offsetting weak demand for equipment.
In the advanced therapies sector, the company experienced above-average growth. Revenue decreased by 1.9% compared to the previous year. The EMEA region posted a sales increase of 5.9%, while revenue decreased by 9.7% in the Americas.
Despite a cautious investment environment, the company expects to achieve its 2024 targets. It remains positive about its long-term outlook thanks to increasing approvals and the development of new biopharmaceutical treatments.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news